Nature Communications (Mar 2017)
A potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologue
- Ebere Sonoiki,
- Caroline L. Ng,
- Marcus C. S. Lee,
- Denghui Guo,
- Yong-Kang Zhang,
- Yasheen Zhou,
- M. R. K. Alley,
- Vida Ahyong,
- Laura M. Sanz,
- Maria Jose Lafuente-Monasterio,
- Chen Dong,
- Patrick G. Schupp,
- Jiri Gut,
- Jenny Legac,
- Roland A. Cooper,
- Francisco-Javier Gamo,
- Joseph DeRisi,
- Yvonne R. Freund,
- David A. Fidock,
- Philip J. Rosenthal
Affiliations
- Ebere Sonoiki
- Department of Medicine, University of California
- Caroline L. Ng
- Department of Microbiology and Immunology, Columbia University Medical Center
- Marcus C. S. Lee
- Department of Microbiology and Immunology, Columbia University Medical Center
- Denghui Guo
- Department of Medicine, University of California
- Yong-Kang Zhang
- Anacor Pharmaceuticals
- Yasheen Zhou
- Anacor Pharmaceuticals
- M. R. K. Alley
- Anacor Pharmaceuticals
- Vida Ahyong
- Department of Biochemistry and Biophysics, Howard Hughes Medical Institute, University of California
- Laura M. Sanz
- Malaria Discovery Performance Unit, Diseases of the Developing World, Tres Cantos Medicines Development Campus,GlaxoSmithKline
- Maria Jose Lafuente-Monasterio
- Malaria Discovery Performance Unit, Diseases of the Developing World, Tres Cantos Medicines Development Campus,GlaxoSmithKline
- Chen Dong
- Anacor Pharmaceuticals
- Patrick G. Schupp
- Department of Microbiology and Immunology, Columbia University Medical Center
- Jiri Gut
- Department of Medicine, University of California
- Jenny Legac
- Department of Medicine, University of California
- Roland A. Cooper
- Department of Natural Sciences and Mathematics, Dominican University of California
- Francisco-Javier Gamo
- Malaria Discovery Performance Unit, Diseases of the Developing World, Tres Cantos Medicines Development Campus,GlaxoSmithKline
- Joseph DeRisi
- Department of Biochemistry and Biophysics, Howard Hughes Medical Institute, University of California
- Yvonne R. Freund
- Anacor Pharmaceuticals
- David A. Fidock
- Department of Microbiology and Immunology, Columbia University Medical Center
- Philip J. Rosenthal
- Department of Medicine, University of California
- DOI
- https://doi.org/10.1038/ncomms14574
- Journal volume & issue
-
Vol. 8,
no. 1
pp. 1 – 11
Abstract
Benzoxaboroles have been shown to be active against different pathogens. Here, the authors show that the benzoxaborole AN3661 inhibitsPlasmodium falciparum in vitroand in mouse models, and identify a homologue of a mammalian cleavage and polyadenylation specificity factor as a drug target.
